VLDL and Atherosclerosis

Endothelial Dysfunctions in Vascular Disease

Volumn , Issue , 2007, Pages 85-94

  Nilsson, Jan ^a   Ares, Mikko P S ^a   Dichtl, Wolfgang ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Atherosclerosis; Cardiovascular diseases; Lipoprotein lipase; Triglyceride metabolism; Very low density lipoproteins

Indexed keywords

EID: 84889855121     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470988473.ch5     Document Type: Chapter

References (47)

1. Tomkin GH, Owens D. Abnormalities in apo B-containing lipoproteins in diabetes and atherosclerosis.Diabetes Metab Res Rev 2001;17:27-43.
2. Karpe F. Postprandial lipoprotein metabolism and atherosclerosis. J Intern Med 1999;246:341-55.
3. Shelness GS, Sellers JA. Very-low-density lipoprotein assembly and secretion. Curr Opin Lipidol 2001;12: 151-157.
4. Hyson D, Rutledge JC, Berglund L. Postprandial lipemia and cardiovascular disease. Curr Atheroscler Rep 2003; 5:437-444.
5. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979;60:473-485.
6. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, Part I. Circulation 2001;104:2376-2383.
7. Shah PK, Kaul S, Nilsson J, et al. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, Part II. Circulation 2001;104:2498-2502.
8. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B-12B.
9. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86:943-949.
10. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219.
11. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-1184.
12. Jeppesen J,Hein HO, Suadicani P, et al. Triglyceride concentration and ischemic heart disease: an eight-year follow- up in the Copenhagen Male Study. Circulation 1998;97:1029-1036.
13. Karpe F, Steiner G, Uffelman K, et al. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
14. Sharrett AR, Patsch W, Sorlie PD, et al. Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb 1994;14:1098-1104.
15. Gronholdt ML, Nordestgaard BG, Wiebe BM, et al. Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. Circulation 1998; 97:34-40.
16. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-369.
17. Ross R.Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
18. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-1695.
19. Jovinge S, Hamsten A, Tornvall P, et al. Evidence for a role of tumor necrosis factor-a in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.Metabolism 1998;47:113-118.
20. Gronholdt ML, Sillesen H, Wiebe BM, et al. Increased acute phase reactants are associated with levels of lipoproteins and increased carotid plaque volume. Eur J Vasc Endovasc Surg 2001;21:227-234.
21. Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003;107: 391-397.
22. Fredrikson GN,Hedblad B, Nilsson JA, et al. Association between diet, lifestyle, metabolic cardiovascular risk factors, and plasma C-reactive protein levels. Metabolism 2004;53:1436-1442.
23. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000;2:200-207.
24. Yla-Herttuala S, Palinski W, Rosenfeld ME, et al. Lipoproteins in normal and atherosclerotic aorta. Eur Heart J 1990;11(Suppl E):88-99.
25. Rapp JH, Lespine A, Hamilton RL, et al. Triglyceriderich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb 1994;14:1767-1774.
26. Mamo JC, Proctor SD, Smith D. Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis 1998;141(Suppl 1):S63-S69.
27. Proctor SD, Mamo JC. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall-evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur J Clin Invest 1998; 28:497-503.
28. Dichtl W, Nilsson L, Goncalves I, et al. Very low-density lipoprotein activates nuclear factor-kappaB in endothelial cells. Circ Res 1999;84:1085-1094.
29. Ares MPS, Kallin B, Eriksson P, et al. Oxidized low-density lipoprotein induces transcription factor AP-1 but inhibits activation of NFkB in human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol, 1995;15: 1584-1590.
30. Takahashi M, Takahashi S, Shimpo M, et al. Beta-very low density lipoprotein enhances inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Atherosclerosis 2002;162:307-313.
31. Stollenwerk MM, Schiopu A, Fredrikson GN, et al. Very low density lipoprotein potentiates tumor necrosis factor-alpha expression in macrophages. Atherosclerosis 2005;179:247-254.
32. Blanco-Colio LM, Valderrama M, Alvarez-Sala LA, et al. Red wine intake prevents nuclear factor-kappaB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia. Circulation 2000;102:1020-1026.
33. Hamsten A,Wiman B, de Faire U, et al. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985;313:1557-1563.
34. Stiko-Rahm A,Wiman B, Hamsten A, et al. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 1990;10:1067-1073.
35. Nilsson L, Gafvels M,Musakka L, et al. VLDL activation of plasminogen activator inhibitor-1 (PAI-1) expression: involvement of the VLDL receptor. J Lipid Res 1999; 40:913-919.
36. Dichtl W, Ares MP, Stollenwerk M, et al. In vivo stimulation of vascular plasminogen activator inhibitor-1 production by very low-density lipoprotein involves transcription factor binding to a VLDL-responsive element. Thromb Haemost 2000;84:706-711.
37. Nilsson L, Banfi C, Diczfalusy U, et al. Unsaturated fatty acids increase plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vasc Biol 1998;18:1679-1685.
38. Hennig B, Meerarani P, Ramadass P, et al. Fatty acidmediated activation of vascular endothelial cells. Metabolism 2000;49:1006-1013.
39. Hennig B, Toborek M, McClain CJ. High-energy diets, fatty acids and endothelial cell function: implications for atherosclerosis. J Am Coll Nutr 2001;20:97-105.
40. Yla-Herttuala S, Lipton BA, Rosenfeld ME, et al. Macrophages and smooth muscle cells express lipoprotein lipase in human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991;88:10143-10147.
41. De Caterina R, Cybulsky MI, Clinton SK, et al. The omega-3 fatty acid docosahexaenoate reduces cytokineinduced expression of proatherogenic and proinflammatory proteins in human endothelial cells. Arterioscler Thromb 1994;14:1829-1836.
42. De Caterina R, Liao JK, Libby P. Fatty acid modulation of endothelial activation. Am J Clin Nutr 2000;71:213S-223S.
43. Endres S, Ghorbani R, Kelley VE, et al. The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 1989;320: 265-271.
44. Toborek M, Lee YW, Garrido R, et al. Unsaturated fatty acids selectively induce an inflammatory environment in human endothelial cells. Am J Clin Nutr 2002;75: 119-125.
45. de Haan LH, Bosselaers I, Jongen WM, et al. Effect of lipids and aldehydes on gap-junctional intercellular communication between human smooth muscle cells. Carcinogenesis 1994;15:253-256.
46. Toborek M, Blanc EM, Kaiser S, et al. Linoleic acid potentiates TNF-mediated oxidative stress, disruption of calcium homeostasis, and apoptosis of cultured vascular endothelial cells. J Lipid Res 1997;38:2155-2167.
47. Carluccio MA, Massaro M, Bonfrate C, et al. Oleic acid inhibits endothelial activation: a direct vascular antiatherogenic mechanism of a nutritional component in the Mediterranean diet. Arterioscler Thromb Vasc Biol 1999;19:220-228.